These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8427723)

  • 1. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 2. Itasetron. DAU 6215, U 98079.
    Drugs R D; 1999 Oct; 2(4):243-4. PubMed ID: 10659399
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
    Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
    J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical development of an antiemetic in oncology. A meta-analysis].
    Pérez Campos A
    Med Clin (Barc); 1994 Sep; 103(8):281-6. PubMed ID: 7967877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
    Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
    J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial.
    Newcomer JW; Faustman WO; Zipursky RB; Csernansky JG
    Arch Gen Psychiatry; 1992 Sep; 49(9):751-2. PubMed ID: 1514881
    [No Abstract]   [Full Text] [Related]  

  • 8. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
    J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 10. Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat.
    Lucot JB
    Pharmacol Biochem Behav; 1989 Jan; 32(1):207-10. PubMed ID: 2734331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors].
    Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H
    C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F.
    Mele PC; McDonough JR; McLean DB; O'Halloran KP
    Eur J Pharmacol; 1992 Aug; 218(2-3):229-36. PubMed ID: 1330594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride.
    Barnes NM; Costall B; Ironside JW; Naylor RJ
    J Pharm Pharmacol; 1988 Sep; 40(9):668. PubMed ID: 2907045
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
    Hayashi H; Miwa Y; Ichikawa S; Yoda N; Miki I; Ishii A; Kono M; Yasuzawa T; Suzuki F
    J Med Chem; 1993 Mar; 36(5):617-26. PubMed ID: 8496941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
    Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ
    Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret.
    Bhandari P; Andrews PL
    Eur J Pharmacol; 1991 Nov; 204(3):273-80. PubMed ID: 1663456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 20. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.